PureTech-founded Seaport reports positive GlyphAgo phase 1 data
(Alliance News) - PureTech Health PLC on Tuesday highlighted positive phase 1 data from Seaport Therapeutics Inc for GlyphAgo, supporting plans to advance the experimental treatment into mid-stage trials for generalised anxiety disorder. Read More